Cargando…
Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database
BACKGROUND: Publication bias compromises the validity of evidence-based medicine, yet a growing body of research shows that this problem is widespread. Efficacy data from drug regulatory agencies, e.g., the US Food and Drug Administration (FDA), can serve as a benchmark or control against which data...
Autores principales: | Turner, Erick H., Knoepflmacher, Daniel, Shapley, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308934/ https://www.ncbi.nlm.nih.gov/pubmed/22448149 http://dx.doi.org/10.1371/journal.pmed.1001189 |
Ejemplares similares
-
Assessment of Public Opinion on Transparency at the US Food and Drug Administration
por: Azad, Tej D., et al.
Publicado: (2022) -
Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications
por: Moreno, Santiago G, et al.
Publicado: (2009) -
Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials
por: Driessen, Ellen, et al.
Publicado: (2015) -
Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review
por: Mazhar, Faizan, et al.
Publicado: (2021) -
Spin in RCTs of anxiety medication with a positive primary outcome: a comparison of concerns expressed by the US FDA and in the published literature
por: Beijers, Lian, et al.
Publicado: (2017)